BioSpace News Archive

Intercept Pharmaceuticals, Inc. announced a restructuring to strengthen the Company’s focus on rare and serious liver diseases and significantly reduce operating expenses, including discontinuing all nonalcoholic steatohepatitis -related investment.

Zura Bio Limited, a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced it will be added to the Russell 2000® and Russell 3000® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023.

Akero Therapeutics, Inc. announced two presentations of secondary and post-hoc analyses of the Phase 2b HARMONY study of efruxifermin in patients with pre-cirrhotic nonalcoholic steatohepatitis, fibrosis stage 2 or 3.

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST) today announced financial and operational results for the fiscal year ended March 31, 2023.

Nevro Corp. today announced that data from an analysis of the 24-Month SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT), the largest RCT to evaluate spinal cord stimulation (SCS) to treat PDN, will be presented at the American Diabetes Association (ADA) 83rd Scientific Sessions to be held June 23-26, 2023 in San Diego, CA.

Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on June 15, 2023 for patent application 17/568,999, “Abuse and Misuse Deterrent Transdermal Systems” which covers its Aversa™ abuse deterrent technology.

scPharmaceuticals Inc. today announced that it expects to be added to the small cap Russell 2000 ® and broad market Russell 3000 ® Indexes at the conclusion of the Russell US Indexes annual reconstitution, effective when the US market opens on June 26, 2023, according to a preliminary list of additions posted on May 19, 2023.

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) is pleased to announce that it will be featured as a presenting company at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference.

BioVie Inc. today announced that the Company will be added as a member of the US small-cap Russell 2000® and Russell 3000® Indexes, effective after the US market opens on June 26, as part of the 2023 Russell indexes reconstitution.

Q BioMed Inc. provides an update to shareholders.